Influencing cellular regeneration processes in the heart has been a long-standing goal in cardiovascular medicine. To some extent, this has been successful in terms of vascular regeneration as well as intercellular connective tissue remodeling processes. Several components of today's routine heart failure medication influence endothelial progenitor cell behavior and support collateral vessel growth in the heart, or have been shown to prevent or reverse fibrosis processes. Cardiomyocyte regeneration, however, has so far escaped therapeutic manipulation strategies. Delivery of exogenous cells of bone marrow origin to the human myocardium may improve heart function, but is not associated with relevant neomyogenesis. However, accumulating evidence indicates that the myocardium contains resident cardiac progenitor cells (CPC) that may be therapeutically useful. This notion indeed represents a paradigm shift but is still controversial. The purpose of this review is to summarize the rapidly expanding current knowledge on CPC, and to assess whether it may be translated into solid therapeutic concepts.
The rationale for research on cardiac progenitor cells
The myogenic failure of noncardiac adult stem cells Given the palliative nature of today's interventional and pharmacologic therapeutic options, the demand for novel curative strategies to treat heart failure is tremendous. The idea of balancing cardiomyocyte loss by adding exogenous cells has evolved since the early 1990s and is indeed intriguing (Figure 1 ). Clinical application of the promising experimental concept of transplanting contractile cells, however, has failed so far. All the more exiting was the notion that adult progenitor cells harvested from bone marrow may regenerate infarcted myocardium. Both cellular marrow compartments, hematopoietic and stroma cells, have been extensively studied in animal models of heart disease as well as in clinical trials. Regarding cells of primarily hematopoietic lineage (CD45 pos , CD34 pos , CD133 pos ) and early (CD31 pos /CD34 pos / CD45 pos ) or late (CD31 pos /CD34 pos /CD45 neg ) endothelial progenitor cells, most investigators feel that their cross-lineage plasticity is not sufficient to allow for differentiation into functional cardiomyocytes [Murry et al. 2004 ]. On the other hand, several groups have provided compelling evidence of at least partial acquisition of a cardiomyocyte phenotype under in vitro and in vivo conditions ]. Mesenchymal stem cells from bone marrow stroma or other sources may have a greater myogenic potential, but only under the influence of DNA demethylating agents [Hattan et al. 2005] . Moreover, clonally expandable bone marrow stem cells that do not express markers of hematopoietic or mesenchymal lineage and regenerate several myocardial constituents have also been described [Yoon et al. 2005] , but it remains to be determined whether those provide a clear advantage over traditional marrow stem cells in terms of their cardiomyocyte differentiation potential.
Clinical cell therapy experience
In line with the limited capacity of marrowderived adult stem cells to attain a cardiomyocyte phenotype, the clinical testing of bone-marrowderived cell transplantation into the heart has so far produced only very modest results ( Figure 2 ). Intracoronary infusion of bone marrow mononuclear cells or enriched progenitor cell products in patients with acute and subacute myocardial infarction has been shown to moderately improve several heart function parameters, but other groups failed to detect any relevant benefit (reviewed and meta-analyzed by Abdel-Latif et al. [2007] , Lipinski et al. [2007] and Martin-Rendon et al. [2008a , 2000b ). Direct intramyocardial delivery of marrow-derived cells, performed either during an open surgical procedure or by using catheter-based injection devices may yield better results, but definitive proof from large multicenter trials is still lacking [Stamm et al. 2007 [Stamm et al. , 2003 ]. Mobilization of bone marrow cells into the peripheral circulation with granulocyte colony stimulating factor (G-CSF) has also provided ambiguous clinical results and raised safety concerns (reviewed by Zohlnhofer et al. [2008] ). The only clinically available cell progenitor type with an explicit myogenic phenotype, satellite cells, has failed clinical efficacy trials, mainly because those skeletal myoblasts and their progeny are not integrated into the myocardial syncytium [Menasche et al. 2008 ]. There may still a supporting role for marrow-derived cells in terms of angiogenesis or vasculogenesis, modulation of the local inflammatory milieu, and antiapoptotic effects on ischemic cardiomyocytes; for a functionally relevant increase in net cardiomyocyte number, however, other sources need to be exploited. To what extent the two groups and their cell populations overlap is not known.
Cardiac cell turnover
Traditionally, the mammalian heart is considered a 'post-mitotic' organ, because cardiomyocyte proliferation ceases around the time of birth. In a recent study on human fetuses -neonates and infants with congenital heart disease, for instance -Amir and colleagues confirmed that cardiomyocyte proliferation indicated by Ki67 expression sharply declines at birth, the frequency of Ki67 pos cardiomyocytes falling below 1% at 20 days postnatally [Amir et al. 2008] . A similar timecourse was observed regarding the postnatal decline of 'adult-type' cardiac progenitor cells expressing c-kit pos and Nkx2.5 (see later), which decreased but remained detectable. However, remnants of embryonic development expressing stem cell markers SSEA-4, Oct3/4, or Isl-1 pos could only be detected in few, if any, of the postnatal tissue samples.
Cells from extracardiac sources populate the heart throughout life. This has been conclusively proven by examining hearts after gender mismatched organ transplantation. When a female has received a male bone marrow transplant, donor cells can be detected in the heart many years after the transplantation, predominately in coronary vessels but also in the myocardium [Jiang et al. 2004; Thiele et al. 2004; Bittmann et al. 2003; Deb et al. 2003 ]. Similar observations have been made in donor hearts from females transplanted into male recipients [Minami et al. 2005; Hocht-Zeisberg et al. 2004; Fogt et al. 2003; Laflamme et al. 2002; Bayes-Genis et al. 2002] . It has now been widely accepted that the coronary microvasculature as well as the fibroblast and smooth muscle components of the myocardium are subject to significant cell turnover. Regarding postnatal myocyte replacement, however, studies of the frequency of mitotic cell division in adult human hearts gave inconsistent results [Beltrami et al. 2001] , and quantitatively relevant cardiomyocyte division in response to disease is considered unlikely by many [Meckert et al. 2005] .
Mitotic replication of mature cardiomyocytes
The main adaptive response to myocyte loss or increased workload in adult mammalian hearts is an increase in cardiomyocyte diameter, or hypertrophy. This notion is based on the lack of macroscopically observable regeneration in patients with myocardial infarction and on the sparse and highly controversial data on mitotic configuration of cardiomyocyte nuclei and expression of nuclear proliferation markers in mature cardiomyocytes [Beltrami et al. 2001] . In experimental models, however, it is possible to force adult cardiomyocytes to leave the G 0 resting phase and re-enter the S-phase (DNA synthesis) of the cell cycle. In cell culture, a variety of growth factors have been shown to induce DNA synthesis as measured by thymidine or BrdU incorporation assays (reviewed by Pasumarthi and Field [2002] ). In vivo, these phenomena are more difficult to quantify, but the rate of DNA synthesis in mouse hearts has been found to be exceedingly low [Soonpaa and Field, 1997 ]. However, DNA synthesis does not necessarily result in genome duplication, genome duplication does not necessarily result in karyokinesis (partition of the nucleus), and karyogenesis does not necessarily result in cytokinesis -division of the cell [Meckert et al. 2005; Pasumarthi and Field, 2002] . Each of these transition points is controlled by a unique set of factors, notably cyclins and cyclin-dependent kinases. When, for instance, cyclin D1 is overexpressed in mouse hearts, increased DNA synthesis results in the formation of multinucleated cardiomyocytes (karyokinesis), but cytokinesis as the final step in mitotic cell division does not occur ]. More promising results in terms of the completion of mitotic cell division have been achieved by genetic manipulation of the cyclins D2 and A2. Targeted overexpression of cyclin D2 in the mouse heart led to enhanced DNA synthesis in response to myocardial infarction, associated with a marked regression of infarct size [Pasumarthi et al. 2005] . Cyclin A2, which is normally silenced in postnatal cardiomyocytes, is known to control the transition from G1 to the S-phase (DNA synthesis) as well as from G2 to M, the entry into mitosis [Chaudhry et al. 2004 ]. Its constitutive overexpression in the postnatal mouse heart led to cardiomyocyte mitosis and cardiac enlargement under baseline conditions, and induced myocardial regeneration and improved heart function after myocardial infarction [Cheng et al. 2007 ]. Taken together, it seems that a regenerative effect can indeed be induced by forcing mammalian cardiomyocytes to re-enter the cell cycle. A safe clinical application of this therapeutic concept in the near future, however, is rather unlikely.
Cardiac progenitor cells
Today, many consider the heart an organ with a substantial intrinsic stem cell pool that may be responsible for a baseline turnover of myocardial cells under normal conditions and serves as a reservoir for regeneration after cell loss as well as for adaptive responses to increased load. The existence of progenitor cells in skeletal muscle tissue has long been known [Anderson, 2006; Mauro, 1961] , and such skeletal myoblasts or satellite cells have been extensively used in experimental and clinical cardiac cell therapy studies [Menasche et al. 2001; Chiu et al. 1995] . Satellite cells efficiently regenerate skeletal myofibers, but the capacity to transdifferentiate towards nonmuscle cell types [Goodell et al. 2001 ] is probably limited to perivascular cells residing in skeletal muscle (see below). In vivo acquisition of a cardiomyocyte phenotype that would allow for functional integration of satellite cells in the heart, however, does not occur . The presence of similar progenitor cells in the postnatal myocardium used to be deemed impossible, but recent experimental data indicate that resident myocardial progenitor cells indeed exist in adult mammalian hearts, and are involved in physiologic regeneration processes. Some, but not all of those cell types display the classic stem cell criteria, namely selfrenewal, multi-or pluripotency, and the capacity for clonal expansion. In the literature, the terms 'cardiac stem cells' and 'cardiac progenitor cells' are often used indiscriminately, but the hallmarks of a true stem cell have not been demonstrated for all cardiac cell populations with a stem cell-like phenotype. Hence, the term 'cardiac progenitor cell' (CPC) will be used throughout this paper.
C-kit pos cardiac progenitor cells
In 2003, Beltrami et al. [2003] reported on the isolation of cells from adult rat hearts that were c-kit pos , Lin neg , CD45 neg and CD34 neg . C-kit, the equivalent of CD117, is a receptor tyrosine kinase that acts as the receptor for stem cell factor (SCF) and was initially used to identify hematopoietic stem cells. C-kit pos cells were present in the myocardium in a proportion of 1:10 000 myocytes, but other groups have described a higher frequency [Messina et al. 2004 ]. They were clonogenic and able to give rise to myocytes, smooth muscle cells and endothelial cells, formed spheroid aggregates in culture that resemble embryoid bodies, and created a band of neomyocardium after injection in infarcted rat hearts. In a canine large animal model, the same group isolated self-renewing, clonogenic and multipotent c-kit pos , MDR1 pos and Sca-1 pos cells, and showed that these can be activated in vivo so as to induce cardiac regeneration [Linke et al. 2005] . Similarly, Yang et al. [2008] isolated c-kit pos cells from rat hearts that co-expressed myogenic transcription factors GATA-4 and MEF 2c as well as markers of mature cardiomyocytes such as troponin-I, -sarcomeric actinin and connexin-43. Again, these cells seemed to be able to proliferate and to regenerate infarcted myocardium. In an interesting experiment, Steele et al. [2005] isolated and expanded c-kit pos Sca-1 pos CD34 neg cells from myocardium of EGFPexpressing mice. When these cells were injected into the pericardial space of healthy GFP neg mice, they migrated throughout the heart but retained a primitive undifferentiated morphology. However, when injected into the pericardial space of Apo-E-deficient mice with coronary vasculopathy, progenitor-like cells trafficked into myocardium, and GFP pos cells differentiated into endothelial cells and, rarely, smooth muscle cells and cardiomyocytes. The pro-angiogenic effects of c-kit pos CPC were also studied by Tillmanns et al. [2008] who showed that c-kit pos CPCs, activated with IFG-1 and HGF and injected near the site of occlusion in rats, engrafted within the host myocardium forming temporary niches. Mediated by hypoxia-inducible factor-1 (HIF-1), which promoted the synthesis and secretion of stromal-derived factor 1 from hypoxic coronary vessels, CPC formed different types of coronary vessels. This increase in vascularization more than doubled myocardial blood flow in the infarcted myocardium, attenuated postinfarct ventricular dilation, reduced infarct size and improved contractile function.
Sca-1 pos cardiac progenitor cells Several other groups based the identification of CPC mainly on expression of Sca-1 (stem cell antigen-1). Sca-1 was also originally used to enrich murine hematopoietic stem cells and is now frequently employed to isolate putative stem cells from parenchymal organs. Its function in cells of hematopoietic lineage is still not clearly defined [Holmes and Stanford 2007] . While Sca-1 pos cells have been identified in murine myocardium with a frequency of up to 17% (OH), their CPC character is determined by co-expression of other markers such as c-kit, CD34, or side population properties (see later) [Martin et al. 2004; Matsuura et al. 2004; Messina et al. 2004 ]. They display clonogenicity and 'cardiosphere' formation [Messina et al. 2004] , and differentiate into myocytes and endothelial cells, and regenerate the myocardium in in vivo infarctiom models. They also showed mesenchymal stem cell characteristics in terms of osteogenic and adipogenic differentiation [Matsuura et al. 2004 ].
Side population cardiac progenitor cells
The third feature that has been used for CPC isolation from rodent myocardium is the extrusion of the DNA-binding dye Hoechst 33342, which requires expression of the ATP-binding cassette transporter proteins ABCG2 (BCRP) or MDR-1 (ABCB1) [Martin et al. 2004] . They have been termed side population (SP) cells because they appear on the side of the FACS bulk population. SP cells are also Sca-1 pos and have been described as c-kit pos or c-kit low . They can be clonally expanded, form 'cardiospheres', and differentiate into myocytes in vitro. Tomita et al. [2005] reported that SP cells make up 3.5% of the heart cells in 2-day-old mice, but the proportion of myocardial SP cells decreased rapidly to only 0.02% at 6 weeks. In response to myocardial injury, the number of SP cells in the heart rises approximately three-fold, but it remains unclear whether this increase is due to resident SP cell proliferation or immigration from the bone marrow ].
Islet-1 pos cardiac progenitor cells Clearly distinct from CPCs identified by c-kit and/or Sca-1 expression or SP properties are cardiac progenitor cells that express islet-1. This LIM-homeodomain transcription factor is expressed during embryologic development and controls the development of the right ventricle and the outflow tracts. Isl-1 pos cells have been identified predominantly in the right heart of neonatal mice and humans and are negative for adult stem cell markers Sca-1, c-kit or CD31. Laugwitz et al. [2005] described the identification of isl1 pos cardiac progenitors in postnatal rat, mouse and human myocardium. Using Cre/lox technology, they were able to selectively mark and purifiy Isl-1 pos CPC and their progeny. In vitro co-culture studies with neonatal myocytes indicated that isl1 pos cells represent authentic, endogenous cardioblasts that efficiently convert to a mature cardiac phenotype. Subsequently, the same group performed genetic fate-mapping studies to document that isl1 pos precursors from the second heart field can generate all cardiovascular cell typesendothelial, cardiomyocyte, smooth muscle, and conduction system -in vivo [Moretti et al. 2006 ]. They derived multipotent isl1 pos cardiovascular progenitor cells (MICP) from embryonic stem cells and showed that isl1 pos /Nkx2.5 pos /flk1 pos give rise to all cardiac lineages in vivo. These data not only demonstrate that muscle and endothelial lineage diversification during embryologic cardiogenesis occurs as a single cell-level decision of a multipotent isl1 pos progenitor cell, but also suggest ESC-derived cardiac progenitors as a possible substrate for therapeutic cardiac regeneration. Isl-1 expression is downregulated as soon as the cells adopt a differentiated phenotype, [Laugwitz et al. 2008 ] and it is not surprising that the neonatal remnants of Isl-1 pos cardiac progenitor cells, when cultured and expanded in vitro, possess the ability to express cardiomyocyte-specific genes and ultimately obtain a phentotype comparable with that of neonatal cardiomyocytes. Since the frequency of Isl-1 pos cells sharply declines after birth, however, their value for myocardial regeneration therapies in adults is probably limited.
Human CPC
In parallel with the discovery of stem-like cells in rodent hearts, CPC were also identified in postnatal human myocardium. In 2003, Urbanek et al. [2003] reported the detection of c-kit pos , Sca-1 pos and MDR pos CPC in myocardium of patients with aortic stenosis who underwent valve replacement. In conjunction with the intense upregulation of cell cycle-associated proteins, this finding suggested that not only hypertrophy but also stem cell-based hyperplasia occurs in response to pressure overload in human hearts. Subsequently, the same group studied myocardial samples from persons who died from acute myocardial infarction and from patients with chronic ischemic cardiomyopathy [Urbanek et al. 2005] . They reported that the number of c-kit pos , MDR pos and Sca-1 pos CPC increased markedly in acute and, to a lesser extent, in chronic infarcts. CPC mitotic index and myocardial lineage commitment increased more in acute infarcts, and a large proportion of CPC in chronic heart failure patients showed signs of ageing (p16ink4a-p53 expression, short telomeres and apoptosis). The authors thus speculated that a 'loss of functionally competent CPCs in chronic ischemic cardiomyopathy may underlie the progressive functional deterioration and the onset of terminal failure'. Messina et al. [2004] described the isolation of cardiosphereforming cells by sprouting from human myocardial tissue samples. The cells were c-kit pos , CD34 pos and CD31 pos and obtained a myogenic phenotype when co-cultured with rat cardiomyovcytes. By transplantation into infarcted mouse myocardium, histologic evidence of neomyogenesis was obtained. Bearzi et al. [2007] detected clusters of c-kit pos CPC residing in niches within adult human myocardium, where they remain connected with surrounding myocytes via cell-cell communications. Human c-kit pos CPC were isolated by immunomagnetic selection following enzymatic dissociation. They were clonogenic, self-renewing and multipotent, differentiated into myocytes, endothelial cells and smooth muscle cells, and regenerated infarcted myocardium in mice and rats. By spontaneous in vitro emigration from right ventricular biopsy samples, Smith et al. [2007] cultivated cells that aggregate to form cardiospheres and are mainly c-kit pos and CD105 pos . When co-cultured with rat cardiomyocytes, they obtained a cardiomyocyte phenotype including appropriate Ca 2þ transients, transmembrane ion fluxes and action potentials. Van Vliet et al. [2008] identified Sca-1 pos cells in human fetal ventricular myocardium and adult atrial tissue samples by immunohistology, and then isolated them. The fetal cells were Sca-1 pos CPC were CD105 pos , CD45 neg , CD34 neg , CD133 neg , CD14 neg , did not express the pluripotent stem cell marker Oct4 but did express the cardiac transcription factors GATA4 and Nkx2.5. Following cultivation and DNA-demethylation with 5'-azacytidine, spontaneously beating cell aggregates and expression of several markers of mature cardiomyocytes were observed. On a more cautionary note, Pouly and colleagues [2008] studied endomyocardial biopsies from adult patients who had undergone heart transplantation as well as right atrial appendage tissue from cardiac surgical patients. They identified a small number of c-kit pos cells in all samples, but the c-kit signal did not co-localize with other stemness markers such as MDR-1 and Isl-1, or with cardiac lineage markers such as Nkx2.5. Instead, The c-kit pos cells showed several phenotypic characteristics of mature mast cells (CD45, tryptase) [Pouly et al. 2008 ]. The authors concluded that the frequency of true CPC in adult humans is probably too low to be exploited for therapeutic applications.
How to identify and obtain CPC Morphologic identification of CPC within the myocardium can be performed by using standard immunohistology methods, but unambiguous in situ identification based on two or more markers usually requires laser scanning confocal microscopy technology. Exact quantification of CPC frequency, however, is difficult and requires mathematic modeling to estimate both CPC and mature cardiomyocyte number. Isolation of CPC for further in vitro characterization or experimental therapeutic use requires that CPC are liberated from the solid myocardium. Often, myocardial samples are dissociated by enzymatic digestion and cardiomyocyte debris is removed by centrifugation. The resulting cell suspension theoretically contains CPC, endothelial cells, fibroblasts and smooth muscle cells. CPC can now be isolated by surface maker labeling and magnetic bead separation [Van Vliet et al. 2008] followed by cultivation and expansion in medium that contains fetal calf serum. Any such protocol involves a great deal of cell manipulation and is inevitably associated with cell loss and phenotypic alterations. For more gentle CPC isolation from small human myocardial biopsy samples, tissue fragments can be placed directly in a fibronectin-coated culture dish. CPC-like cells will spontaneously grow out of the tissue [Smith et al. 2007 ]. When those are detached and reseeded, they can form spheroid aggregates termed cardiospheres, which consist mainly of c-kit pos and CD105 pos cells but also of MSClike CD90 pos cells and endothelial-type CD34 pos CD31 pos cells.
The ex vivo proliferation rates of human CPC are rather slow, limiting their potential clinical usefulness. Formation of cardiospheres in standard culture conditions usually takes 2-3 weeks but can be accelerated. Bartosh et al. [2008] demonstrated that seeding of canine CPC on poly-L-ornithine led to cardiosphere formation within 2-3 days, and also seemed to improve CPC resistance to oxidative stress [Bartosh et al. 2008 ]. Cultivation of Isl-1 pos CPC on a cardiac mesenchymal feeder layer has been shown to preserve their capacity to self-renew and to adopt a fully differentiated cardiomyocyte phenotype [Laugwitz et al. 2005] . Similarly, c-kit pos Sca-1 pos CPC isolated by in vitro migration from murine myocardium have been shown to proliferate better when co-cultured with bone marrow cells [Steele et al. 2005 ].
The origin of adult CPC Given the successful isolation of myocardial cells with stem cell properties by several independent groups, the existence of CPC seems to be unambiguously proven. Nevertheless, it is unlikely that the heart harbors several distinct pluripotent stem cell populations, and many researchers thus believe that the various immunologic phenotypes represent different maturation stages of one cell type. They appear to reside in specific niches within the myocardium, where the composition of surrounding cells and extracellular matrix components is responsible for preservation of CPC in an undifferentiated state. A completely unresolved question is the origin of CPC; that is, are CPC primary cardiac cells or have they migrated to the heart from the bone marrow? None of the stem cell markers used for CPC identification is truly cardiac-specific; indeed all of the key CPC markers described above have first been used for labeling of bone marrow stem cells, and are found in numerous other tissues. Some CPC phenotypes are negative for the typical hematopoiesis-related surface antigens CD34 and CD45, but it has been well established that trafficking of bone marrow stem cells to nonmarrow organs can be associated with a loss of hematopoietic stem cell markers [Qian et al. 2008 ]. On the other hand, the primarily 'adult' hematopoietic stem cell marker c-kit is also expressed on cardiac progenitor cells during embryologic development. For instance, Wu et al. [2006] isolated Nkx2.5 pos cells from in vitro differentiated murine embryonic stem cells and found that approximately 28% of these cells expressed c-kit and differentiated into both cardiomyocytes and smooth muscle cells. Other evidence supporting a primary cardiac origin of CPCs is the expression of cardiac transcription factors such as GATA4, Nkx2.5 or MEF 2C, which have been shown in SP CPCs or c-kit pos CPC under baseline conditions or in response to DNA demethylation by 5 0 -azacytidine [Oh et al. 2003 ]. Recently, Boni et al. [2008] showed that Nkx2.5 is a target gene of Notch1, a plasma membrane receptor that plays multiple roles during embryologic development and appears to regulate myocyte commitment in the adult heart. However, it should be noted that few if any myocardial transcription factors are truly cardiac specific. GATA4, for instance, is also expressed in early mesoderm and plays a role in liver and lung formation [Ackerman et al. 2007; Dame et al. 2004; Nemer and Nemer, 2003 ].
The views regarding the origin of postnatal CPC -the heart or the bone marrow -do not have to be mutually exclusive. Using a mouse model of bone marrow reconstitution with constitutively GFP-expressing cells followed by myocardial infarction, Mouquet and colleagues demonstrated that local cell proliferation helps maintain the cardiac SP number under normal conditions. Following depletion by myocardial infarction, however, cardiac SP cells are reconstituted both through proliferation of resident cells and through homing of bone marrow-derived cells to areas of myocardial injury. Upon arrival in the heart, the marrow cells obtain a cardiac SP-specific immunophenotype and become indistinguishable from primary cardiac CPC.
Other progenitor cell populations in the heart All of the above resident CPC populations have in common that they were identified in niches within the myocardium. In addition, cells with cardiac progenitor-like properties have also been detected in nonmuscular components of the heart and may be summarized as epicardial stem cells (see later). Other recent developments are the proposed persistence of neural crestderived cells in postnatal mammalian hearts, and the emerging understanding of perivascular cells as a reservoir of tissue resident stem cells. It cannot be excluded that one or more of those cell populations are related to the above described 'typical' CPC but so far they are treated as separate entities in the scientific literature.
Epicardial/pericardial stem cells Pericardium, epicardium and subepicardial adipose tissue also seem to contain precursor cells that might be useful for cardiac regeneration therapies. Originally, the epicardium is epithelial tissue and covers the mesenchymal myocardium. Later during embryologic development, some of the epicardial cells undergo epithelial-tomesenchymal transformation and migrate into the myocardium, where they differentiate into fibroblasts and smooth muscle cells and participate in the formation of coronary vessels and the fibrous skeleton of the heart [Winter and Gittenberger-De Groot, 2007; Wada et al. 2003 ]. This occurs under the influence of connective tissue cell growth factors such as BMPs, TGF-b and FGF, but stimulation by pro-angiogenic growth factors such as VEGF may also guide epicardial-derived cells towards endothelial/ hematopoietic differentiation [Wessels and Perez-Pomares, 2004] . A supporting role of the epicardium in formation of the myocardium has been clearly demonstrated [Gittenberger-De Groot et al. 2000 , 1998 ] and adult human epicardial cells can express cardiac marker genes such as GATA4 and troponin I in vitro [Van Tuyn et al. 2007 ], but differentiation of epicardial cells into cardiomyocytes in vitro has been ruled out by most researchers [Lie-Venema et al. 2007 ]. Very recent evidence, however, indicates that stem-like cells residing in the epicardium cells can indeed participate in myocardial generation and regeneration. For example, Limana et al. [2007] identified c-kit pos and CD34 pos cells in fetal and adult human epicardium that acquire an endothelial phenotype in vitro and express early (Nkx2.5) and mature (GATA4) cardiomyocyte-specific transcription factors. In mice, c-kit pos epicardial stem cells proliferate and migrate into the myocardium in response to myocardial infarction [Limana et al. 2007 ]. Zhou et al. [2008] identified a novel cardiogenic precursor in the epicardium of embryonic mouse hearts that expresses the transcription factor Wt1. Wt1 pos proepicardial cells seem to share a developmental origin with multipotent Nkx2-5 pos and Isl1 pos progenitor cells and a subset of these Wt1 pos precursors differentiated into fully functional cardiomyocytes [Zhou et al. 2008] . Similarly, Cai et al. [2008] observed that progenitor cells expressing the T-box transcription factor Tbx18 migrate to form the epicardium and then make a substantial contribution to the formation of ventricular myocytes. Finally, it should also be noted that there are substantial fat accumulations in the subepicardial space in many humans, and adipose tissue has also been suggested as a source of myogenic stem cells. For instance, Yamada et al. [2007] isolated CD133 pos CD45 neg cells from brown adipose tissue in mice, which were able to obtain several immunophenotypic and morphologic features of cardiomyocytes and also helped push bone marrow cells toward a myogenic phenotype.
Neural crest-derived cells
In addition to primary myocardial CPC, the adult heart also seems to contain stem-like cells of neural crest origin. During embryologic development, neural crest cells with ectodermal and mesenchymal roots migrate to the heart, participate in the separation of the aortic and the pulmonary outflow tracts and play a key role in formation of the cardiac conduction system [Gurjarpadhye et al. 2007; Rosenquist and Finnell, 2007; Kirby et al. 1983] . Recent evidence indicates that the progeny of those cells may persist in the adult heart and add to the resident cardiac progenitor cell pool. Nestin pos neurallike stem cells were detected in postinfarct rat myocardium, suggesting that they are recruited to or proliferate in the infarcted heart and contribute to innervation of the scar El-Helou et al. 2005 ]. El-Helou et al.
[2008] described how nestin pos cells, upon injection into infarcted rat hearts, migrate to the infarct region, participate in reparative fibrosis and serve as a substrate for de novo blood vessel formation. Tomita et al. [2005] isolated Hoechst 33342 excluding SP cells from neonatal and adult rodent hearts after enzymatic dissociation. As expected, those cells readily formed 'cardiospheres'. At day 0 most cardiosphere-derived cells were positive for the neural stem cell markers nestin and Musashi-1 but had lost these markers by day 14. Upon differentiation, some of the cardiosphere cells obtained a neural cell phenotype and expressed the peripheral nerve cell markers peripherin, p75 NGF receptor, MAP2, and Hu, and activated the neuron-specific 1-tubulin promoter. Following transplantation into chick embryos, those cardiosphere-derived cells migrated to the truncus arteriosus and cardiac outflow tract and contributed to nerve and smooth muscle cell formation [Hu et al. 2008] . Lineage studies using a double transgenic 0-Cre/ Floxed-EGFP mouse model revealed undifferentiated and differentiated neural crest-derived cells in the fetal myocardium. The authors concluded that neural crest-derived cells migrate into the heart, remain there as dormant multipotent stem cells and, when activated, differentiate into cardiomyocytes, neurons, glia or smooth muscle cells.
Perivascular cells
Another interesting novelty is the identification of perivascular cells that co-express myogenic and endothelial cell markers and have a robust myocyte differentiation capacity. Such myoendothelial cells are found among pericytes and have been isolated from various human tissues including skeletal muscle, pancreas, adipose tissue and placenta. They are discussed as representing the solid-organ reservoir of tissue-specific mesenchymal stem cells [Caplan, 2008; Crisan et al. 2008] and express CD146, NG2 and PDGF-Rb but no hematopoiteic, endothelial or myogenic markers. Myoendothelial cells from skeletal muscle have been shown to be more efficient for induction of myocardial regeneration than conventional skeletal muscle progenitors (satellite cells) and endothelial cells. To date, it is unclear whether there is a relationship between CPC and myoendothelial cells, but the concept of the perivascular space as reservoir for resident stem cells is certainly appealing in an organ as highly vascularized as the heart [Tamaki et al. 2002] . Very recently, Galvez and colleagues provided a first link between CPC and pericytes. They isolated CPC termed 'cardiac mesangioblasts' by spontaneous in vitro emigration from juvenile mouse hearts, which were Sca-1 pos , c-kit pos , CD34 pos , CD44 pos , CD31 pos and CD45 neg , and formed clonal aggregates [Galvez et al. 2008] . So far, those cells resemble cardiosphere-forming cells isolated via heart tissue outgrowth by other groups. When exposed to low serum concentration, they spontaneously differentiated into phenotypically and functionally competent cardiomyocytes. Of note, the authors traced the origin of these cardiac mesangioblasts to a CD31 pos /34 pos and NG2 pos subpopulation of perivascular cells that resemble myoendothelial cells from other tissues. On the other hand, when mesangioblasts from fetal mice were injected into infarcted mouse hearts, they colonized mainly the smooth muscle layer of blood vessels [Galli et al. 2005] . Nevertheless, they still exerted several protective effects on ischemic cardiomyocytes in that model. Hence, the perivascular niche that is increasingly recognized as a major reservoir for mesenchymal stem cells and their putative tissue-specific progeny also seems to play a role in the heart and its cellular homeostasis.
Heart disease and cardiac progenitor cells
The discovery of several types of cardiac progenitor cells in adult hearts is at odds with the paucity of intrinsic myocardial regeneration after myocardial infarction. This discrepancy might be explained by the observation that CPC succumb to ischemic cell death just like mature cardiomyocytes. Indeed, the center of a myocardial infarction area is devoid of viable CPC, while most of the CPC proliferation activity seems to be concentrated in the infarct border zone [Urbanek et al. 2005; Beltrami et al. 2001] . Chronic ischemic heart failure has also been shown to decrease the pool of viable and functional CPC via oxidative damage-induced apoptosis [Urbanek et al. 2005] . Although functionally competent and proliferating CPC remain detectable in the myocardium of old patients with decompensated heart failure ], CPC -as well as mature cardiomyocytes -are subjected to ageing processes [Torella et al. 2004] . Gonzalez et al. [2008] showed that, while the overall number of c-kit pos Lin neg CPC in ageing rats increased, the majority of these cells have a senescent phenotype with expression of p16ink4a and shortened telomers, resulting in a sharp decline of functionally competent CPC. The activation-relevant IGF, and HGF signaling systems appeared also to be disturbed in ageing CPC, and the HGFdependent migration of CPC within the heart was also subject to age-related impairment. On the other hand, the authors determined that there is a high degree of neocardiomyocyte formation in ageing hearts, interpreted as an attempt to compensate for age-related myocyte loss. In part, these data seem to be at odds with the study performed by Hsieh et al. [2007] . In a fate-mapping study in double transgenic mice with conditional (tamoxifen-inducible) GFP expression in cardiomyocytes, they determined that during normal ageing for up to 1 year, the cardiomyocyte pool is not refreshed. Only in response to myocardial infarction or pressure overload did the percentage of GFPþ cardiomyocytes decrease, indicating neomyogenesis originating from stem or precursor cells in a magnitude of 10-20%.
Within the physiologic niche of CPC, Notch signaling seems to regulate CPC activity and commitment. In situ, CPC possess the Notch1 receptor, and the supporting cells exhibit the Notch ligand Jagged1 [Boni et al. 2008 Martin et al. [2008] showed that in murine cardiac SP cells, Abcg2, the ABC transporter protein that confers the ability to extrude Hoechst 33342 (see 4.3), is upregulated by HIF2-and promotes a cytoprotective transcriptional response by inducing antioxidant stress pathways. Consequently, overexpression of Abcg2 resulted in increased peroxide degradation and promoted cell viability.
Pharmacologic targeting of cardiac progenitor cells
Once the mechanisms that induce CPC activation, proliferation and differentiation have been understood, the door is open to develop strategies to provoke their activation and/or enhance their proliferation and differentiation in vivo. Several attempts have already been undertaken in experimental models. For more than 10 years it has been known that IGF-1 can induce hyperplastic growth in postnatal hearts [Reiss et al. 1996 ]. Initially, this was attributed to cell cycle re-entry of mature cardiomyocytes [Reiss et al. 1997] . Given the emerging CPC concept, however, the myocardial effects of IGF-1 have been revisited and further clarified. The effect of growth factors on CPC activation in ischemic hearts was studied by Linke et al. [2005] in a canine model. They isolated clonogenic c-kit pos , MDR pos Sca-1 pos CPC, confirmed that they give rise to cardiomyocytes, smooth muscle cells and endothelial cells, and determined that both HGF and IGF-1 have powerful chemoattractant and/or antiapoptotic effects on them. Then, both growth factors were injected into dog hearts with myocardial infarction. Within 4 hours, HGF and IGF treated infarct tissue contained viable CPC that expressed Ki67 as an indicator of cell proliferation, while in control hearts all CPC had undergone apoptotic cell death. After 4 weeks, evidence of pronounced cardiomyocyte proliferation was detected by histology, associated with partial recovery of contractile function in growth factor treated hearts [Linke et al. 2005 ].
The same group recently also showed that IGF and HGF treatment can reverse the age-related impairment of heart function in rat via CPC activation, indeed extending the life span of treated animals .
Another strategy to enhance CPC functionality is the activation of signaling cascades that inhibit apoptosis, which has already been proven very efficacious in the context of cardiac cell therapy with bone marrow MSC [Mangi et al. 2003 ]. In transgenic mice with cardiac-specific expression of nuclear-targeted Akt (Akt/nuc), Gude et al. [2006] found prolonged postnatal cell cycling as evidenced by increased numbers of Ki67 pos cardiomyocytes at 2 to 3 weeks after birth [Gude et al. 2006 ]. Similarly, Akt promoted expansion of c-kit pos CPC, as well as their myocyte commitment as evidence by increased Nkx 2.5 or MEF 2C expression. At least with respect to their growth factor and cytokine expression profile, Akt appears to induce a neonatal phenotype in adult myocardium.
Conclusion
The concept of exploiting cardiac progenitor cells for myocardial regeneration is clearly the most intriguing of all currently known cell therapy strategies. Nevertheless, several fundamental issues still need to be addressed. The most obvious question is: Why does the heart not regenerate in so many patients if it really contains substantial numbers of powerful tissue-specific stem cells? Is cardiac progenitor cell function impaired in patients with severe heart disease? The Anversa group explains this apparent discrepancy with the death of CPC within areas of myocardial infarction [Torella et al. 2007 ]. The very disease that produces the need also destroys the basis of regeneration. However, this sensitivity of CPC to ischemia and disease is surprising because quiescent stem-like cells should have minimal energy requirements as compared with working cardiomyocytes. For comparison, skeletal muscle progenitor or satellite cells are known to have a marked tolerance to hypoxia and ischemia. Similarly, the question of why there is so little regeneration in nonischemic heart disease needs to be addressed. At the same time, it seems logical that the presumed balance between cardiomyocyte loss and CPC regeneration can only be preserved within certain limits, and severe injury overwhelms the heart's intrinsic regenerative capacity. Even in typical regenerating tissues such as liver, skin or bone marrow, injury or disease can result in organ failure when a certain threshold is exceeded [Michalopoulos and Defrances, 1997] .
Although all of the major breakthroughs in the field of CPC have been reported by the same research group and many still await independent confirmation, the existence of cells that express stem cell-typical markers in the heart cannot be doubted ( Figure 3 ). Emigration of cells from myocardial tissue cultures that form spherical structures and show many progenitor cell properties ('cardiospheres') can easily be reproduced. Nevertheless, the authors of this review still have doubts as to the power of CPC to regenerate the heart in a clinically relevant fashion. Much of the data regarding cardiomyogenic differentiation of CPC resembles the early reports on bone marrow stem cell plasticity, where cells needed to be co-cultured with cardiomyocytes or subjected to DNA-demethylation in order to achieve a cardiomyocyte phenotype. None of the above c-kit pos or Sca-1 pos CPC display spontaneous cardiomyocyte differentiation. The stressed myocardium has long been known to switch to a fetal gene program as a protective mechanism [Rajabi et al. 2007 ] and to what extent this regression to a prenatal phenotype is associated with the expression of stemness markers remains to be determined. CPC represent an existing field of research that may eventually lead to superior clinical concepts for treatment of heart failure. Nevertheless, research on exogenous cardiomyocyte replacement cells must also continue, as long as clinical-grade CPC regeneration in heart failure patients has not been proven feasible, safe, and efficacious.
